BCR and aneurysmal bone cyst: In order to establish whether mutational status of lymphoma cells in vitro is predictive of response to the BCR inhibitors ibrutinib and idelalisib, we tested their effect on the ABC DLBCL cell lines OCI-LY10, U-2932 and also on the GBC DLBCL line SU-DHL-6 that is not anticipated to be affected by the BTK inhibitor ibrutinib, but potentially by PI3K inhibition using idelalisib.